Procter & Gamble Health Ltd.
Q3FY23 Quarterly Result Announced for Procter & Gamble Health Ltd.
Pharmaceuticals firm Procter & Gamble Health announced Q3FY23 (quarter ending June) results:
- Total sales of Rs 316.3 crore for the quarter ended March 31, 2023, vs Rs 262.2 crore, a year ago, up by 21%.
- Profit After Tax (PAT) was Rs 59.2 crore, up by 16% vs a year ago.
- Sales for the nine-month period ending March 31, 2023, was Rs 912.8 crore vs Rs 803.2 crore a year ago.
- PAT for a nine-month period was Rs 199.7 crore vs Rs 151.4 crore a year ago, despite the high inflationary pressures
Mr. Milind Thatte, Managing Director, P&G Health India, said, “We continue to register a consistent growth in this quarter despite a challenging macro-economic environment. This has been made possible through our integrated growth strategies of expanded reach and improved productivity, while we continue to create awareness among our patients and consumers alike. The cornerstone of our approach continues to be our robust product line, which helps meet the rising demand for daily supplements, thereby helping us deliver the 6th consecutive quarter of strong growth. Our focus brands, Evion, Neurobion and Livogen continue to perform exceptionally well. The quarter also saw Neurobion regain its position as India’s No. 1 Nerve Care Brand, while Livogen’s exceptional performance continued behind the award winning campaign ‘Na Na Anemia’ with Diagnostic camps across the country. Under our flagship CSR Program, SEHAT, in partnership with Tata Trust’s ‘Yes! To Poshan’Program, we continued to showcase our commitment towards the cause of maternal & child health.”.
“The quarter also saw us receive various prestigious recognitions. We are thankful to the CSR Summit and Awards 2023, CII, Exchange4media and Obesity International for recognizing our Corporate Social Responsibility and Consumer Awareness efforts. These recognitions have further fueled our passion and commitment to serve Indian consumers and help them live healthier lives,” he concluded.